There are currently 2707 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Neuroblastoma Biology Study
NCT01587300
Recruiting
Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma... Read More
Gender:
ALL
Ages:
Between 31 days and 99 years
Trial Updated:
09/01/2024
Locations: Children's Hospital Boston, Boston, Massachusetts
Conditions: Neuroblastoma
Register for Updates
Oral Ketamine for Treatment of Vaso-Occlusive Pain
NCT05378555
Recruiting
The purpose of this study is to learn more about the feasibility of oral ketamine for the treatment of painful sickle-cell crises in children and adolescents as a supplement to intravenous (IV) opioids. There is a need for improved non-opioid analgesia for patients experiencing sickle-cell crises in the hospital and prehospital setting, as children and adolescents with sickle cell disease who experience sickle-cell crises often have severe pain that is not well controlled by high dose opioids, l... Read More
Gender:
ALL
Ages:
Between 12 years and 24 years
Trial Updated:
08/30/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Vaso-occlusive Crisis
Register for Updates
ENCALM: a Study of ENX-102 As a Monotherapy Treatment in Patients with Generalized Anxiety Disorder
NCT05749055
Recruiting
The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/29/2024
Locations: Boston Clinical Trials, Boston, Massachusetts
Conditions: Generalized Anxiety Disorder
Register for Updates
TRUDI: TDXD+Durva in HER2+/low IBC
NCT05795101
Recruiting
The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer. The names of the study drugs involved in this study are: * Trastuzumab deruxtecan * Durvalumab
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
Register for Updates
Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
NCT06488378
Recruiting
This research is being done to evaluate the safety and tolerability of the new drug, axatilimab, in combination with olaparib (a standard of care treatment) in Breast Cancer 1/2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The names of the study drugs involved in this study are: * Axatilimab (a type of antibody) * Olaparib (a type of PARP inhibitor)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
Register for Updates
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors
NCT05593094
Recruiting
This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors with or without brain metastases. The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Dana-Farber Cancer Insitute, Boston, Massachusetts
Conditions: Advanced Solid Tumors, HER2-positive Breast Cancer
Register for Updates
Epilepsy Learning Healthcare System (ELHS)
NCT06265103
Recruiting
The Epilepsy Learning Health System (ELHS) is a quality improvement and research network to improve outcomes for people with epilepsy. The ELHS is designed as a model of value-based chronic care for epilepsy as envisioned by the National Academies of Medicine Committee in their landmark reports "The Learning Health System" and "Epilepsy Across the Spectrum: Promoting Health and Understanding". The ELHS network is a collaboration among clinicians, patients and researchers that promotes the use o... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/28/2024
Locations: Partners - Massachusetts General Hospital Epilepsy Service (MGH)/ Partners - Brigham and Women's (BWH), Boston, Massachusetts +1 locations
Conditions: Epilepsy, Seizure Disorder, Neurologic Disorder, Rare Diseases
Register for Updates
Continuous Glucose Monitoring (CGM) in Long Term Care (LTC) Facilities
NCT05711108
Recruiting
To prospectively determine the burden of hypoglycemia (minutes spent below 70 mg/dl per day, measured by continuous glucose monitor (CGM)) among residents of long term care facilities (LTC) with a diagnosis of type 1 or type 2 diabetes including key clinical subgroups (living in skilled nursing facility (SNF) or nursing home (NH), on different hypoglycemic medications). This aim will be achieved by recruiting 300 residents with diabetes in 4 LTC facilities. All participants will undergo masked... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/28/2024
Locations: Joslin Diabetes Center, Boston, Massachusetts
Conditions: Diabetes, Hypoglycemia, Aging
Register for Updates
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
NCT00131014
Recruiting
The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Disease, Leukemia, Lymphocytic, Chronic, Lymphoproliferative Disorders
Register for Updates
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NCT04756726
Recruiting
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin's
Register for Updates
CLOZAPINE Response in Biotype-1
NCT04580134
Recruiting
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/27/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Register for Updates
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06067841
Recruiting
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates